Arstat Pharmaceuticals is advancing transformational products that focus on significant unmet needs in women's health. Protected by 11 granted U.S. patents and a European (EPO) patent, the pipeline includes four drug candidates with proven efficacy and safety. Two products are Phase III-ready (confirmed by the FDA), and two other products are ready for Phase IIb. An addressable U.S. market is approximately 50 million women, with projected peak U.S. gross sales exceeding $3.5 billion. This is arguably one of the very best pharmaceutical portfolios in women's health. Arstat's most valuable asset is Nuvocept – the first and only oral contraceptive designed explicitly for overweight and obese women. The FDA has already endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the US contraceptive market and address a high public health priority in the post-Roe world. The Company's Founder and acting CEO, Arkady Rubin, Ph.D., with 30 years of industry experience (J&J, Pfizer). Dr. Rubin is a co-inventor of Ortho Tri-Cyclen Lo, the top-selling oral contraceptive in the U.S., with peak sales of over $500M/year. In addition, we are engaged in proprietary R&D activities. We developed and patented two transformational women's health products: NUVOCEPT - the first and only oral contraceptive designed for overweight and obese women (≈60% of 10 million US pill users). Protected by 3 US patents. PREMRING - first-in-class vaginal ring for uterine fibroids and endometriosis (a much-needed solution for >15 million US women). Protected by a US patent. Please visit the company's website (www.arstatinfo.com) for further details.